Genesis Biopharma and Lonza have signed a process development and scale-up agreement for to the manufacture of Contego, Genesis Biopharma’s autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma. Contego is a ready-to-infuse cell therapy based on currently available therapies at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.  “We are pleased to have such an experienced bioprocess ...